Certain Balance Sheet Components

12 Months Ended

Mar. 31, 2026

Certain Balance Sheet Components [Abstract]

Accrued Expenses

Accrued expenses at March 31, 2026 and 2025 consisted of the following (in thousands):


	March 31, 2026		March 31, 2025

Research and development expenses	$	92,749	$	45,813
Compensation-related expenses	87,325		53,928
Other expenses	25,749		14,553
Total accrued expenses	$	205,823	$	114,294

As of March 31, 2026, accrued research and development expenses included an accumulated accrual of $42.5 million of non-cancelable contractual costs as a result of the discontinuation of batoclimab, of which $39.0 million was recognized as research and development expense during the year ended March 31, 2026.